CLINICAL RESEARCH MANAGEMENT OFFICEThe Clinical Research Management Office (CRMO) is a shared resource of the Kimmel Cancer Center (KCC).The CRMO collaborates with physicians, scientists and support staff in the development and implementation ofKimmel Cancer Center clinical trials. The CRMO staff provides a broad range of services tailored to the specificneeds of the investigator and his/her support staff. Through these efforts the CRMO has established itself as thecenter of all activities related to KCC clinical trials.
Specific aims of the CRMO include: Facilitate the development of clinical trials within the Kimmel Cancer Center Coordinate the preparation and submission of studies for review by the CCRC and the ThomasJefferson University Institutional Review Board Collect, abstract, maintain and update data specific to patients entered into clinical trials Maintain a centralized data base of patients participating in Kimmel Cancer Center clinical trials develop and maintain an ongoing quality assurance program that will ensure the accuracy of data ensure that oncology clinical trials (studying the biology, diagnosis and treatment of patients withmalignant disease) are conducted according to federal, state and institutional regulations provide information and administrative support to the Clinical Cancer Research Review Committee(CCRRC) and the KCC Data Safety Monitoring Board (DSMB) provide budget development and fiscal management of funded trials distribute information on active clinical trials to investigators and the general public through the KCCwebsite Coordinate Multidisciplinary Working Group meetings Auditing of Investigator Initiated TrialsThe Kimmel Cancer Center had over 120 open clinical studies in the 1/1/06-12/31/06 time frame with a totalaccrual of 999 subjects; 287 to therapeutic and 712 to non-therapeutic and prevention trials. Investigator-initiatedtrials (therapeutic) patient accrual total was 168 while there were 651 patients accrued to non therapeuticinvestigator initiated trials and 90 patients accrued to cooperative group trials in the 1/1/06-12/31/06 time frame.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA056036-09
Application #
7712934
Study Section
Subcommittee G - Education (NCI)
Project Start
2008-09-05
Project End
2013-05-31
Budget Start
2008-09-05
Budget End
2009-05-31
Support Year
9
Fiscal Year
2008
Total Cost
$115,192
Indirect Cost
Name
Thomas Jefferson University
Department
Type
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Rappaport, Jeffrey A; Waldman, Scott A (2018) The Guanylate Cyclase C-cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia. Front Oncol 8:299
Pandya, Kalgi D; Palomo-Caturla, Isabel; Walker, Justin A et al. (2018) An Unmutated IgM Response to the Vi Polysaccharide of Salmonella Typhi Contributes to Protective Immunity in a Murine Model of Typhoid. J Immunol 200:4078-4084
Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999
Shafi, Ayesha A; Schiewer, Matthew J; de Leeuw, Renée et al. (2018) Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol 1:325-337
Meyer, Sara E; Muench, David E; Rogers, Andrew M et al. (2018) miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. J Exp Med 215:2115-2136
Mazina, Olga M; Mazin, Alexander V (2018) Reconstituting the 4-Strand DNA Strand Exchange. Methods Enzymol 600:285-305
Magee, Michael S; Abraham, Tara S; Baybutt, Trevor R et al. (2018) Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. Cancer Immunol Res 6:509-516
Chervoneva, Inna; Freydin, Boris; Hyslop, Terry et al. (2018) Modeling qRT-PCR dynamics with application to cancer biomarker quantification. Stat Methods Med Res 27:2581-2595
Capparelli, Claudia; Purwin, Timothy J; Heilman, Shea A et al. (2018) ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Res 78:5680-5693
Nevler, Avinoam; Muller, Alexander J; Cozzitorto, Joseph A et al. (2018) A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. J Am Coll Surg 226:596-603

Showing the most recent 10 out of 807 publications